The Prognostic Impact of Smoking Status, Cessation, and Anticoagulation-Interaction on Adverse Outcomes in Patients with Atrial Fibrillation: A Systematic Review
Keywords:
Atrial Fibrillation, Smoking, Smoking Cessation, Prognosis, Adverse Outcomes, Mortality, Stroke, Bleeding, Systematic ReviewAbstract
Introduction: Atrial fibrillation (AF) and tobacco smoking represent two of the most significant and concurrent global health burdens. While smoking is an established risk factor for the development of incident AF, its prognostic impact following an AF diagnosis has remained controversial, particularly regarding thromboembolic risk (Zhu, Guo, & Hong, 2016). This systematic review synthesizes the evidence on the association between smoking status (current, former, and cessation) and a comprehensive range of adverse outcomes in patients with established AF.
Methods: A systematic review was conducted adhering to PRISMA guidelines. The Cochrane Library, PubMed, and Embase databases were searched for observational studies (cohort or case-control) and meta-analyses evaluating the prognostic impact of smoking in patients with a confirmed AF diagnosis. Methodological quality and risk of bias for all included non-randomized studies were rigorously assessed using the 9-star Newcastle-Ottawa Scale (NOS) (Wells et al., 2000).
Results: A total of 17 high-quality observational studies, including large national cohorts and one key meta-analysis, were included. The evidence was consistent and significant that persistent smoking is associated with increased all-cause mortality (Relative Risk 1.82, 95% CI 1.33–2.49) (Zhu, Guo, & Hong, 2016) and cardiovascular death (RR 1.54, 95% CI 1.31–1.81) (Zhu, Guo, & Hong, 2016). Smoking was also a significant predictor of major bleeding (RR 1.93, 95% CI 1.08–3.47) (Zhu, Guo, & Hong, 2016) and AF recurrence post-catheter ablation (RR 3.19, 95% CI 1.23–8.27) (Okutucu et al., 2010). The association with stroke was contradictory (the "stroke paradox"); a major meta-analysis found no significant link (RR 1.19, 95% CI 0.97–1.46) (Zhu, Guo, & Hong, 2016), while large cohort studies, particularly those in Vitamin K Antagonist (VKA)-treated populations, reported a significant risk (Adjusted Hazard Ratio 1.64–1.66) (Lee et al., 2021; Nakagawa et al., 2015). Critically, smoking cessation after AF diagnosis was associated with a rapid and significant risk reduction for ischemic stroke (aHR 0.702, 95% CI 0.595–0.827) and all-cause death (aHR 0.842, 95% CI 0.748–0.948) compared to persistent smokers (Lee et al., 2021).
Discussion: The data confirm that persistent smoking is a major driver of mortality, major bleeding, and interventional failure in AF patients. The "stroke paradox" is likely not a true null effect but a signal of confounding, specifically an interaction with VKA (e.g., warfarin) therapy, where smoking is known to disrupt anticoagulation control (Nakagawa et al., 2015). This risk may be attenuated in the modern era of Direct Oral Anticoagulants (DOACs).
Conclusion: Persistent smoking is unequivocally associated with a severe adverse prognostic profile in patients with AF. Smoking cessation provides a rapid, substantial, and quantifiable prognostic benefit—reducing stroke and mortality risk—and must be considered a critical, non-negotiable therapeutic intervention on par with anticoagulation and rhythm control.
References
Albertsen, I.E., Rasmussen, L.H., Lane, D.A., Overvad, T.F., Skjøth, F., Overvad, K., Lip, G.Y.H. & Larsen, T.B. (2014). The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. Chest, 145(3), 559–566.
Aune, D., Schlesinger, S., Norat, T. & Riboli, E. (2018). Tobacco smoking and the risk of atrial fibrillation: A systematic review and meta-analysis of prospective studies. European Journal of Preventive Cardiology, 25(13), 1437–1451.
Chamberlain, A.M., Agarwal, S.K., Folsom, A.R., Duval, S., Soliman, E.Z., Ambrose, M., Eberly, L.E. & Alonso, A. (2011). Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm, 8(8), 1160–1166.
Chua, W., D'Elia, N., Eram, H.,... & Fabritz, L. (2021). Efficacy and safety of direct oral anticoagulants (DOACs) vs. warfarin in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. European Heart Journal-Cardiovascular Pharmacotherapy, 7(1), f11-f19.
Dick, P., et al. (2021). Thromboembolic and bleeding events in relation to anticoagulation in atrial fibrillation: A systematic review and meta-analysis. PLoS ONE, 16(5), e0251378.
Goette, A., Lendeckel, U., Kuchenbecker, A., et al. (2007). Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart, 93(9), 1056–1063.
Heeringa, J., Kors, J.A., Hofman, A., Van Rooij, F.J. & Witteman, J.C. (2008). Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. American Heart Journal, 156(6), 1163–1169.
Hindricks, G., Potpara, T., Dagres, N., et al. (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42(5), 373–498.
Hohnloser, S.H., et al. (2012). Efficacy of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation treated in the ROCKET AF trial. JAMA, 308(11), 1107-1113.
Huxley, R.R., & Uthman, O.A. (2019). Smoking and the Risk of Incident Heart Failure: A Systematic Review and Meta-Analysis of 25 Prospective Cohort Studies. JACC: Heart Failure, 7(10), 861-870.
Jain, A., et al. (2021). Abstract 14241: Cigarette Smoke Causes Atrial Fibrillation via PiP2-Dependent IKACh Activation. Circulation, 144(Suppl_1), A14241.
Joglar, J.A., Chung, M.K., Armbruster, A.L., et al. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation, 149(1), e1-e156.
Kato, T., et al. (2016). Factors associated with progression from paroxysmal to persistent atrial fibrillation: A retrospective study. Journal of Arrhythmia, 32(5), 392-397.
Krahn, A.D., Manfreda, J., Tate, R.B., et al. (1995). The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. American Journal of Medicine, 98(5), 476–484.
Kwon, Y., Norby, F.L., Jensen, P.N., Agarwal, S.K., Soliman, E.Z., Lip, G.Y.H., Longstreth, W.T., Jr., Alonso, A., Heckbert, S.R. & Chen, L.Y. (2016). Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). PLoS ONE, 11(1), e0147065.
L'Allier, P.L., et al. (2022). Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes. Open Heart, 9(2), e002012.
Lee, S.R., Choi, E.K., Jung, J.H., Han, K.D., Oh, S. & Lip, G.Y.H. (2021). Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. Journal of Clinical Medicine, 10(11), 2238.
Lip, G.Y.H., et al. (2020). Polypharmacy and Adverse Outcomes in Atrial Fibrillation: A Systematic Review and Meta-Analysis. PLoS ONE, 15(6), e0234375.
Lubitz, S.A., Yin, X., Rienstra, M., et al. (2015). Long-Term Outcomes of Secondary Atrial Fibrillation in the Community: The Framingham Heart Study. Circulation, 131(19), 1648–1655.
Messner, B., & Bernhard, D. (2014). Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(3), 509-515.
Mills, E.J., et al. (2014). Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 129(1), 28-41.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine, 6(7), e1000097.
Nakagawa, K., Hirai, T., Ohara, K., Fukuda, N., Numa, S., Taguchi, Y., Dougu, N., Takashima, S., Nozawa, T. & Tanaka, K. (2015). Impact of persistent smoking on long-term outcomes in patients with nonvalvular atrial fibrillation. Journal of Cardiology, 65(5), 429–433.
Okutucu, S., Aytemir, K., et al. (2010). Effect of cigarette smoking on the risk of atrial fibrillation recurrence after pulmonary vein isolation. Journal of Arrhythmia, 26(1), 21-29.
Pawar, P.P., Jones, L.G., Feller, M., Guichard, J.L., Mujib, M., Ahmed, M.I., Roy, B., Rahman, T., Aban, I.B., Love, T.E., White, M., Aronow, W.S., Fonarow, G.C. & Ahmed, A. (2012). Association between smoking and outcomes in older adults with atrial fibrillation. Archives of Gerontology and Geriatrics, 55(1), 85–90.
Plakoyiannig, E., et al. (2013). Heart failure and atrial fibrillation: a community-based cohort study. Circulation: Heart Failure, 6(4), 738-746.
Shah, M., et al. (2021). Major adverse cardiovascular events in atrial fibrillation patients: A retrospective primary care cohort study. Frontiers in Cardiovascular Medicine, 8, 728217.
Shinton, R., & Beevers, G. (1989). Meta-analysis of relation between cigarette smoking and stroke. BMJ, 298(6676), 789–794.
Steffel, J., et al. (2021). 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 23(10), 1612-1676.
Suzuki, S., Otsuka, T., Sagara, K., Semba, H., Kano, H., Matsuno, S., Takai, H., Kato, Y., Uejima, T., Oikawa, Y., et al. (2017). Effects of Smoking on Ischemic Stroke, Intracranial Hemorrhage, and Coronary Artery Events in Japanese Patients With Non-Valvular Atrial Fibrillation. International Heart Journal, 58(4), 506–515.
Tedrow, U.B., Conen, D., Ridker, P.M., Cook, N.R., Koplan, B.A., Manson, J.E., Buring, J.E. & Albert, C.M. (2010). The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). Journal of the American College of Cardiology, 55(21), 2319–2327.
van den Ham, H.A., et al. (2023). Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and vitamin K antagonists in atrial fibrillation. Frontiers in Pharmacology, 14, 1125576.
Wells, G.A., Shea, B., O’Connell, D., et al. (2000). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Retrieved from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Wolf, P.A., D'Agostino, R.B., Kannel, W.B., Bonita, R., & Belanger, A.J. (1988). Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA, 259(7), 1025–1029.
World Health Organization (WHO). (2023). Tobacco. Fact Sheet.
Wu, P., et al. (2015). The efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis. Circulation: Cardiovascular Quality and Outcomes, 8(2), 196-205.
Zhu, W., Guo, L. & Hong, K. (2016). Relationship between smoking and adverse outcomes in patients with atrial fibrillation: a meta-analysis and systematic review. International Journal of Cardiology, 222, 289–294.
Zuo, H., Nygård, O., Vollset, S.E., Ueland, P.M., Ulvik, A., Midttun, Ø., Meyer, K., Igland, J., Sulo, G. & Tell, G.S. (2018). Smoking, plasma cotinine and risk of atrial fibrillation: the Hordaland Health Study. Journal of Internal Medicine, 283(1), 73–82.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Siti Tari Salsa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
